The advantages of RabMAb®primary antibodies stem from the uniqueness of the rabbit immune system.
Overview of the rabbit immune system
Our RabMAb® technology enables the development of high-affinity, high-specificity antibodies to challenging targets. Ourselves and others have observed that compared to mice and other rodents, rabbits:
Mount immune responses against a broader range of antigens
Undergo more somatic gene conversion
Possess longer and more heterogeneous CDR3 sequences
In addition, the rabbit spleen, the typical source of antibody-producing cells for generation of hybridomas, is larger and contains more cells than a mouse spleen.
The combination of these properties results in a wider range of antibodies and therefore a better chance of finding the right experimental tools than with traditional technologies.
Rabbit monoclonals, for example, have on average 10-100x higher affinity than mouse monoclonals and are often better at detecting subtle differences such as slight sequence variations that distinguish members of a protein family.